All News

It was recently said, in reference to the UK’s Value-Based Assessment(VBA) program, that innovation had not been “tried and tested in the pricing context”.

Few would argue with the desirability of innovation - something new, something that delivers value.

In response to the recent shooting at Fort Hood that killed four (including the killer’s suicide) and wounded 16, the mental health watchdog Citizens Commission on Human Rights (CCHR) views this and other recent incidents as a wake-up call to the dangers of antidepressants.

The new Internet Library from the European Patients’ Academy (EUPATI) will come online towards the end of 2015.

On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec.

On March 21, 2013, the United States Senate approved an amendment by a vote of 79 to 20 to repeal the 2.3 percent medical device excise tax.

Cash-strapped states are shifting patients from traditional fee-for-service Medicaid coverage to managed Medicaid plans.

In our second Q&A installment previewing next month’s iPharma2014 conference in New York City, we spoke with David Stern.

A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.

In 1995, there were 16 million internet users - or 0.4% of the world’s population. In just 17 years, this figure has grown to 2.4 billion and 34.3% adoption.

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.

Since the early days of the internet, we’ve been busy creating websites and other digital channels.

The European Parliament yesterday voted towards the adoption of the new Clinical Trials Regulation.

A number of top management positions at the Center for Drug Evaluation and Research (CDER) need to be filled.

Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides-at least-to every question.

Over the next few years, med tech company Becton Dickinson will launch up to 30 generic, pre-filled syringes in an attempt to lower medication errors and raise company revenues, according to BD Rx president Mark Sebree.

Patient adherence to medicine is the eternal puzzle for big Pharma: what combinations of financial incentives, personalized interventions, and just good information work best to push down that stubborn 50 per cent abandonment threshold after six months of treatment?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi

The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse.

In January 2013, FDA told manufacturers to lower the dose of zolpidem, the insomnia treatment, for women, and suggested a 10 mg to 5 mg for immediate-release products (Ambien, Edluar, and Zolpimist) and from 12.5 mg to 6.25 mg for extended-release products (Ambien CR).

The global pancreatic cancer treatment market value in the six major countries (U.S., France, Germany, Italy, Spain and the UK) will increase from $529 million in 2012 to $1.63 billion by 2017.

Peter Houston looks at the pharma marketing takeaways from last week’s Digital Innovation Summit.

The National Institute for Health and Care Excellence (NICE) has finally published the formal consultation on value-based assessment (VBA).

With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer.

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.

Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.

A few weeks back I wrote on this blog about the need for CEOs to get social. I’m realistic, I know that the majority of CEOs still don’t engage directly in social media. Mostly it’s “the team” that does it, the marketing team, or the social media team, or the whole team. Great. Have you told them what rules they’re playing by?

Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last week, at a conference organized under the auspices of the Irish Presidency of the European Union and featuring a galaxy of Irish and European stars from the worlds of politics, regulation, research, industry and patients.

Either the doctor’s best friend or nightmare, the e-patient movement (the ‘e’ could stand for engaged or empowered) is here to stay and growing, writes Marylyn Donahue.

Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms.